We have advised Eurofins Scientific (EUFI.PA), the global leader in food testing and a global scientific leader in bioanalytical testing, on its agreement to divest its Digital Testing business to Stirling Square Capital Partners for €220 million on a cash and debt free basis.
Eurofins’ Digital Testing was established in 2015 and has increased substantially in size and profitability over the past few years through organic growth, strategic investments and bolt-on acquisitions to expand its range of digital testing tools and services as well as its global reach. It provides global testing, quality assurance and technical analysis of digital systems, devices, content and cyber security, and is recognised as one of the leading players in its space in terms of technology, innovation and service quality.
For Eurofins, proceeds from the divestment will support the Group’s capital allocation priorities, including capital expenditure in laboratories, digitalisation and acquisitions to further enhance its leadership in bioanalytical testing and other life science areas.
Completion of the transaction is subject to the approval of the relevant authorities and is expected to occur before the end of 2022.
The team was led by corporate partners Angus Miln and David Bates, and senior counsel Paul Thorpe, and was supported by corporate associates Harry Ruffell and Rachael Potts, and partners Paul Callaghan (Employment), Ann Casey (Incentives), Paolo Palmigiano (Competition), Graham Samuel-Gibbon (Tax) and Sian Skelton (Commercial Technology and Data), and associates Katie Lewis (Incentives), Laura Mackay (Commercial Technology and Data), Pip Moss (Tax), Elisabetta Rotondo (Competition) and James Watkins (Employment). Additional international support was provided by Taylor Wessing teams in Shanghai and Hong Kong.
